Younossi Z.M.Stepanova M.Henry L.Han K.-H.Ahn S.H.Lim Y.-S.Chuang W.-L.JIA-HORNG KAONguyen K.V.Lai C.L.Chan H.L.-Y.Wei L.2021-09-042021-09-0420181352-0504https://www.scopus.com/inward/record.uri?eid=2-s2.0-85052488044&doi=10.1111%2fjvh.12965&partnerID=40&md5=5323bb8cf25fe298cdc8b30903b31f0ahttps://scholars.lib.ntu.edu.tw/handle/123456789/581827Although HCV infection is highly prevalent in East Asia, these patients have been underrepresented in HRQL studies. Here, we assess HRQL in East Asian HCV patients treated with different anti-HCV regimens. Patients completed Short Form-36 (SF-36) before, during and after treatment. A total of 989 HCV patients were enrolled in two phase 3 clinical trials [China: 60.2%, South Korea: 22.4%, Taiwan: 17.4%; genotype 1: 55.3%, treatment-na?ve: 57.5%; cirrhosis: 14.0%]. Patients received pegylated interferon, sofosbuvir and ribavirin (Peg-IFN?+?SOF?+?RBV; n?=?130, genotypes 1, 6) or SOF?+?RBV (n?=?475, all genotypes) or SOF and ledipasvir (LDV/SOF; n?=?384, genotype 1). The SVR-12 rates were 94.6%, 96.2% and 99.2%, respectively (P?=?0.005). During treatment, Peg-IFN?+?SOF?+?RBV-treated group experienced significant declines in most HRQL scores (by the end of treatment, mean decline up to ?12.0 points, all P?<?0.05). Patients on SOF?+?RBV had milder HRQL impairment (up to ?5.8 points, P?<?0.05 for 5 of 8 HRQL domains). In contrast, patients receiving IFN- and RBV-free regimen with LDV/SOF had their HRQL scores improve (mean up to +4.3 points, P?<?0.0001 for 3 of 8 scales). In multivariate analysis, receiving Peg-IFN?+?SOF?+?RBV was consistently independently associated with HRQL impairment during treatment (β: ?10.3 to ?16.4) and after achieving SVR-12 (β: ?4.4 to ?9.1) (all P?<?0.01). The results were reproduced in a subgroup of patients enrolled in China. We conclude that in East Asian patients with HCV, HRQL improved from baseline after treatment with LDV/SOF but not with Peg-IFN?+?RBV-containing or Peg-IFN-free RBV-containing regimens. The HRQL impairment associated with the use of Peg-IFN persists even after achieving sustained virologic clearance. ? 2018 John Wiley & Sons Ltddirect-acting antivirals; health-related quality of life; mental health; physical functioning; vitality[SDGs]SDG3alanine aminotransferase; hemoglobin; ledipasvir; peginterferon; sofosbuvir; alpha interferon; antivirus agent; benzimidazole derivative; fluorene derivative; ledipasvir; ribavirin; sofosbuvir; adult; anemia; Article; body mass; drug safety; East Asian; fatigue; female; flu like syndrome; gastrointestinal symptom; genotype; hepatitis C; human; liver cell carcinoma; liver cirrhosis; major clinical study; male; mental disease; musculoskeletal disease; neurologic disease; non insulin dependent diabetes mellitus; phase 3 clinical trial (topic); prevalence; quality of life; questionnaire; Short Form 36; skin manifestation; sustained virologic response; virus load; aged; China; chronic hepatitis C; clinical trial; middle aged; multicenter study; phase 3 clinical trial; South Korea; Taiwan; treatment outcome; Adult; Aged; Antiviral Agents; Benzimidazoles; China; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Quality of Life; Republic of Korea; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Taiwan; Treatment Outcomejournal article10.1111/jvh.12965299746652-s2.0-85052488044